Vaxcyte, Inc. (NASDAQ:PCVX) Receives Average Recommendation of "Buy" from Analysts

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Shares of Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) have been given an average rating of "Buy" by the eleven brokerages that are presently covering the stock, MarketBeat.com reports. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $136.50.

PCVX has been the subject of a number of analyst reports. Cantor Fitzgerald started coverage on shares of Vaxcyte in a report on Tuesday, April 22nd. They issued an "overweight" rating for the company. Cowen reiterated a "buy" rating on shares of Vaxcyte in a research report on Thursday, August 7th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in PCVX. Rhumbline Advisers boosted its stake in shares of Vaxcyte by 5.5% in the first quarter. Rhumbline Advisers now owns 181,230 shares of the company's stock valued at $6,843,000 after purchasing an additional 9,416 shares during the period. PNC Financial Services Group Inc. boosted its stake in shares of Vaxcyte by 5.8% in the first quarter. PNC Financial Services Group Inc. now owns 9,600 shares of the company's stock valued at $362,000 after purchasing an additional 524 shares during the period. Parallel Advisors LLC boosted its stake in shares of Vaxcyte by 203.6% in the first quarter. Parallel Advisors LLC now owns 1,597 shares of the company's stock valued at $61,000 after purchasing an additional 1,071 shares during the period. Envestnet Asset Management Inc. boosted its stake in shares of Vaxcyte by 12.5% in the fourth quarter. Envestnet Asset Management Inc. now owns 55,083 shares of the company's stock valued at $4,509,000 after purchasing an additional 6,121 shares during the period. Finally, Deutsche Bank AG boosted its stake in shares of Vaxcyte by 5.6% in the fourth quarter. Deutsche Bank AG now owns 1,212,706 shares of the company's stock valued at $99,272,000 after purchasing an additional 64,522 shares during the period. Hedge funds and other institutional investors own 96.78% of the company's stock.

Vaxcyte Trading Down 1.9%

Shares of PCVX opened at $32.09 on Tuesday. Vaxcyte has a 12-month low of $27.66 and a 12-month high of $121.06. The firm has a 50-day moving average price of $33.93 and a 200 day moving average price of $45.65. The firm has a market capitalization of $4.17 billion, a P/E ratio of -7.81 and a beta of 1.21.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.10). During the same quarter in the previous year, the firm earned ($1.10) EPS. Equities research analysts predict that Vaxcyte will post -4.21 earnings per share for the current fiscal year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.